Teratogenic action of platinum thymine blue by Beaudoin, Allan R.
Life Sciences, Vol. 31, pp. 757-762 Pergamon Press 
Printed in the U.S.A. 
TERATOGENIC ACTION OF PLATINUM THYMINE BLUE 
Allan R. Beaudoin 
Department of Anatomy and Cell Biology, University of Michigan 
Ann Arbor, Michigan 48109 
(Received in final form June 9, 1982) 
Summary 
The teratogenic activity of the antitumor agent cisplatinum- 
2-thymine (platinum thymine blue) was investigated in rats. Preg- 
nant Wistar-derived albino rats were given single ip injections of 
an aqueous solution of platinum thymine blue (PTB) at one day 
of pregnancy from day 5 through day 14 (sperm day=day 0). The 
dosages used ranged from 20 to 80 mg/kg maternal body weight. At 
autopsy (day 20) fetuses were recovered and subsequently examined 
for skeletal and soft-tissue abnormalities. PTB was embryolethal 
and teratogenic at several stages during rat gestation. Embryonic 
death occurred following all doses, and was dose dependent, except 
at day 5. The majority of malformed fetuses, however, were observed 
only after treatment at day 6 or 7 following injection with 50, 60, 
or 80 mg/kg. Eye defects were the predominant abnormality followed 
by hydrocephalus, gastroschisis, and ectopia cordis. The skeleton 
was only slightly affected. PTB is a potent inhibitor of DNA 
synthesis, but its mechanism of teratogenic action is unknown. 
Rosenberg et al. (I) first reported the antitumor action of coordination 
complexes of platinum. Cis-dicholrodiamineplatinum II (cis-platinum) appears to 
have the most potent activity as a broad spectrum antitumor agent against tumors in 
different animal hosts (2). Some efficacy of cis-platinum II and its analogs 
against human tumors has been reported (5,4). The cis-platinum complexes cause a 
severe and prolonged inhibition of DNA synthesis with minimal effect on RNA and 
protein synthesis (5,6) presumably due to interaction of the platinum molecule with 
DNA (7,8,9). These platinum complexes have been reported to be mutagenic (10,11), 
carcinogenic (12) and teratogenic in mice (15). 
Davidson et al. (14) discovered that cis-platinum II would react with pyrim- 
idines and substituted pyrimidines to form water soluble deep blue complexes, the 
"platinum blues". Their postulated formula for the complexes is PtCsHI4N405. The 
platinum blues have the advantage over cis-platinum II in high soluDiIity in water 
and lack of kidney toxicity, while still being highly potent antitumor agents. The 
platinum pyrimidine blues also react with DNA (15, 16). 
The p l a t i n u m  b l u e s  have not  been t e s t e d  f o r  t e r a t o g e n i c i t y ,  but  because of  
t h e i r  a n t i t u m o r  a c t i v i t y  and r e a c t i v e n e s s  with DNA, they  a re  suspec t .  The p r e s e n t  
s tudy  was under taken  to i n v e s t i g a t e  the  e f f e c t  of  p l a t i num thymine b lue  (PTB) on ra t  
embryogenesis .  
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Materials and Methods 
Virgin female Wistar-derived rats from my colony were used. The animals were 
fed Teklad Rat Diet (Teklad Mills, Winfield, Iowa) ad libitum, with supplemental 
feedings of lettuce. Water was available at all times. The day of finding sperm in 
the vaginal smear was designated day 0 of pregnancy. Aqueous solutions of platinum 
thymine blue (Tousimis Research Corporation, Rockville, Maryland) were prepared for 
ip injection. Solutions were prepared so that the same volume was always injected, 
regardless of the concentration used (0.1 ml/20g body wt). The dose injected was 
either 20,40,50,60 or 80 mg/kg maternal body weight. The toxic level for FTB has 
been reported to be about 450 mg/kg in Swiss Webster mice (14). Controls received 
distilled water ip. 
Pregnancy was terminated at day 20, resorption sites were counted and the 
fetuses recovered, weighed, and fixed in Bouin's fluid or 95% alcohol. Those 
fetuses fixed in Bouin's fluid were subsequently examined for external malfor- 
mations and then free-hand sectioned with a razor blade. These sections are useful 
to detect gross malformations in the palate, brain, eyes, heart, kidney and sex 
organs. Abnormalities in other organs are not identified easily. Fetuses fixed in 
95% alcohol were prepared for staining with alizarin red S for visualization of 
the skeleton. Statistical analyses of the results were performed by the Student's 
"t" test. 
Results 
Table I presents the results following treatment with PTB from day 5 through 
day 14 of gestation. A direct association between the dose injected and embryonic 
death (resorption) is apparent at all treatment days, except at day 5. A similar 
positive correlation occurs between the dose and the incidence of malformed sur- 
vivors at days 6 and 7. Fetal malformations were observed following treatment at 
day 5 through 8, with the greatest number found at day 6 and 7. Malformed fetuses 
usually weighed less than normal fetuses, as reflected in significant reduction in 
fetal weights of litters containing many malformed fetuses. Treatment at days 10 
and 12 also reduced fetal weight, but without concomitant malformations. Daily 
observations of the treated females failed to reveal any overt signs of FTB toxicity 
The weight gained during pregnancy was a reflection of litter size and varied with 
the number of resorptions. 
Table II presents the types of malformations induced by PTB. At all doses 
tested, four malformations predominated: anophthalmia/microphthalmia (ratio of 
44/9), hydrocephalus, gastroschisis, and ectopia cordis. Several additional 
malformations were induced but in much reduced numbers. These included agnathia, 
cleft palate, club feet, diaphragmatic hernia, ectrodactyly, encephalomeningocele, 
exencephaly, renal agenesis, syndactyly and umbilical hernia. 
Almost a l l  o f  t he  malformed f e t u s e s  were induced a f t e r  a dose o f  e i t h e r  50 or  
60 mg/kg, t h e r e f o r e ,  t h e s e  two doses  were used in  ano the r  group of  r a t s  to  look f o r  
s k e l e t a l  a b n o r m a l i t i e s .  A t o t a l  o f  206 f e t u s e s  were examined from dams t r e a t e d  a t  
day 6, 8, 10, 12 and 14. The on ly  ma l fo rma t ion  observed  was r i b  f u s i o n ,  which 
occur red  in  5 o f  30 s u r v i v i n g  f e t u s e s  o f  dams t r e a t e d  wi th  60 mg/kg PTB a t  day 6. 
Absent o s s i f i c a t i o n  c e n t e r s  occur red  wi th  v a r i a b l e  i n c i d e n c e  in  both c o n t r o l  and 
t r e a t e d  f e t u s e s ,  They were absen t  p redominan t ly  in  the  sternum and metacarpus .  In 
60 c o n t r o l  f e t u s e s ,  20.3% had miss ing  me taca rpa l  o s s i f i c a t i o n  c e n t e r s  and 21.7% 
mis s ing  s t e r n a l  o s s i f i c a t i o n  c e n t e r s .  In 206 t r e a t e d  f e t u s e s ,  the  p e r c e n t a g e s  were 
26.2 and 42.7 r e s p e c t i v e l y .  These r e s u l t s  were not  ana lyzed  s t a t i s t i c a l l y .  
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TABLE I 
Embryotoxiclty Following Maternal Injection of PTB 
Day Dosage No. Dams No. % Survivors Fetal Wt (g) 
Treated (mg/kg) Treated Implant. Resorb. Malformed mean ~SD 
Sites No. (%) 
20 5 63 7.9 0 3.93 ±0.14 
40 5 72 13.8 0 3.83 ±0.25 
50 6 86 8.1 2 (2.5) 4.04 ±0.16 
60 6 88 12.5 1 (1.3) 3.76 ±0.08 
80 5 69 4.3 0 3.88 ±0.26 
01 5 68 0 0 3.82 ±0.28 
20 6 98 7.1 0 3.70 ±0.31 
40 6 80 30.0 11(19.6) 3.39 ±0.60 
50 6 81 51.8 11(28.2) 3.05 ±0.552 
60 6 86 67.4 22(78.6) 2.78 ±0.543 
80 4 67 98.5 1 (I00) 3.14 
01 8 92 i.i 0 3.92 ±0.22 
20 3 37 29.7 0 3.80 ±0.35 
40 5 64 66.6 0 3.64 ±0.17 
50 6 81 60.5 3 (9.3) 3.64 ±0.21 
60 i0 121 90.9 7 (63.6) 2.65 ±0.243 
80 5 61 90.1 5 (83.0) 3.12 ±0.413 
01 6 74 1.4 0 3.84 ±0.48 
20 3 33 15.1 0 4.04 ±0.08 
40 5 53 16.9 2 (4.5) 3.67 ±0.33 
50 4 60 50.0 0 3.62 ±0.48 
60 6 71 98.6 1 (i00) 2.92 
80 3 49 95.5 0 3.23 ±0.234 
40 5 65 46.2 0 3.85 ±0.73 
50 3 41 75.6 0 3.36 ±0.68 
60 4 60 78.3 0 3.74 ±0.14 
80 3 46 i00.0 - 
I0 40 3 44 34.0 0 3.31 ±0.21 
50 4 39 94.9 0 2.43 ±0.66 
60 3 44 100 - 
80 3 45 i00 - 
12 50 6 78 50.0 0 2.90 ±0.29 
60 4 52 65.4 0 2.72 ±0.49 
80 3 39 100.0 - 
14 50 5 70 18.6 0 3.58 ±0.32 
80 3 34 i00.0 0 
i. Controls were run at days most susceptible to teratogenic effects of PTB. 
2. P = 0.05 
3. P = 0.02 or less 
4. Only 2 survivors 
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TABLE II 
Major Malformations Following PTB Treatment I 
Day of Dosage Anophthalmia/ Ectopia 
Treatment (mg/kg) Microphthalmia Hydrocephalus Gastroschisis Cordis 
6 40 5111 4111 3111 iiii 
50 4111 2111 - - 
60 20122 10122 7122 5122 
80 1/1 
7 50 2/3 2/3 2/3 - 
60 4/7 5/7 3/7 2/7 
80 4/5 4/5 1/5 1/5 
8 40 2/2 - - - 
60 i/i - - - 
i. Results expressed as number of fetuses with the malformation/total number of 
fetuses with malformations. 
Discussion 
The r e s u l t s  of  t h i s  experiment  demons t ra te  t h a t  the an t i t umor  agent  p l a t i n u m  
thymine b lue  has both  l e t h a l  and t e r a t o g e n i c  e f f e c t s  i n  the  r a t .  With the  dosages 
used,  a p o s i t i v e  c o r r e l a t i o n  was demonstra ted between embryonic death  ( r e s o r p t i o n )  
and the  dose of PTB admin i s t e r ed ,  except  a t  day 5 when the  i n c i d e n c e  of  r e s o r p -  
t i o n s  was s i m i l a r  f o r  a l l  doses .  The reason  the  day 5 embryo i s  more r e s i s t a n t  to 
the  l e t h a l  e f f e c t s  of PTB than  l a t e r  embryonic s t ages  i s  no t  known, bu t  may be 
r e l a t e d  to  i t s  developmental  s t age  ( p r e i m p l a n t a t i o n )  and the  d i s t r i b u t i o n  of PTB. 
Af t e r  a d m i n i s t r a t i o n ,  p l a t i n u m  an t i t umor  agen ts  reach an i n i t i a l  high c o n c e n t r a t i o n  
i n  k idney ,  l i v e r ,  s k i n ,  bone, ovary,  and u t e r u s  (17).  A r a p i d  e l i m i n a t i o n  fo l lows  
wi th  70-90% of the  a d m i n i s t e r e d  dose appear ing  i n  the  u r i n e  w i t h i n  the  f i r s t  few 
days.  The p l a t i n u m  remain ing  i n  sk in ,  muscle ,  and bone forms a r e s e r v o i r  t h a t  
i s  s lowly  d e p l e t e d ,  wi th  p l a t i n u m  s t i l l  d e t e c t a b l e  i n  r a t  u r i n e  30 days a f t e r  a 
s i n g l e  exposure (17).  The t r a n s i e n t  h igh c o n c e n t r a t i o n  of  p l a t i num i n  the 
u t e r u s  may e x p l a i n  i t s  g r e a t e r  l e t h a l i t y  to  the  implanted  embryo. This l e t h a l  
e f f e c t  i s  pronounced a t  a l l  implan ted  s tages  exposed i n  t h i s  exper iment .  (Table I ) .  
Malformations were induced following maternal treatment at day 5, 6, 7, or 8 
with all doses except the 20 mg/kg dose, which failed to induce a malformation at 
any tested time in gestation. The greatest numbers of abnormalities followed 
treatment with 60 mg/kg PTB at day 6 or 7. There were a total of 66 malformed 
fetuses produced following treatment at all days. Maldevelopment of the eye was 
the predominant defect noted. Forty-four fetuses had apparent anophthalmia 
(histological sections were not done) and 9 had microphthalmia. Hydrocephalus 
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was present in 27 fetuses, and 18 fetuses had defects in development of the 
abdominal wall (2 fetuses with ectopia cordis only, 9 fetuses with gastroschisis 
only, and 8 fetuses with ectopia cordis and gastroschisis together). 
Differentiation of the central nervous system and the mesoderm was most 
severly affected by PTB-treatment. In the Wistar rat, the optic evaginations 
from the diencephalon appear at day 9-10 and contact the surface ectoderm at day 
I0-ii. The lens placodes are formed at day 11-12 and detach from the surface 
at day 13-14. During the same period of time, mesodermal cells migrate ventro- 
laterally from the somites to give rise to the developing muscle and connective 
tissue in the lateral body wall folds. These folds meet to form the ventral body 
wall at day 15-14, followed by the normal umbilical herniation. These events are 
dated from a presumed fertilization during the night of mating and, although 
approximate, probably vary no more than plus or minus one-half day (18). Thus, 
critical stages in the embryogenesis of the eye and ventral body wall occur within 
the same time period (day 9 to IS), and an insult during this period could be 
expected to affect the development of both structures. It is difficult to postulate 
the onset of hydrocephalus. It could be early or late in development, but could 
certainly be expected to be induced between days 9 and 13. Why other organs, also 
in critical stages of embryogenesis, are not affected remains an enigma of tera- 
tology. 
Lazar e t  a l .  (13) r epo r t ed  c i s - d i a m i n e d i c h l o r o p l a t i n u m  I I  to be t e r a t o g e n i c  
i n  the  Swiss Webster mouse. They r epo r t ed  reduced f e t a l  weights  and minor s k e l e t a l  
ma l fo rmat ions  of  s t e r n e b r a e ,  r i b s ,  and v e r t e b r a e .  Only one f e t u s  with m u l t i p l e  
ma l fo rma t ions ,  i n c l u d i n g  c l e f t  p a l a t e  and deformed e x t r e m i t i e s ,  was d e s c r i b e d .  
In  the p r e s e n t  s tudy ,  PTB-delayed o s s i f i c a t i o n  was found on ly  i n  the  sternum and 
metacarpus .  However, f i v e  of  the  50 s u r v i v i n g  f e t u s e s  e x h i b i t e d  r i b  f u s i o n s ,  a 
t r u e  morphologica l  d e f e c t .  Rib f u s i o n s  were found on ly  in  f e t u s e s  from dams 
t r e a t e d  a t  day 6 wi th  60 mg/kg of PTB. There a re  four  v a r i a b l e s  t h a t  could e x p l a i n  
the  d i s c r e p a n c i e s  between the  two s t u d i e s .  F i r s t ,  Lazar e t  a l .  used lower doses 
(3 or 8 mg/kg); second, the  mouse was the  exper imen ta l  an imal ;  t h r e e ,  the  drug 
was a d m i n i s t e r e d  on ly  a t  day 8 ( roughly  comparable to day 9 i n  r a t  g e s t a t i o n ) ;  
and four ,  c i s - p l a t i n u m  was used,  no t  PTB. 
The c i s - p l a t i n u m  complexes have been r e p o r t e d  to  induce a severe  and p r o l o n g -  
ed inhibition of DNA synthesis with minimal effects on RNA and protein synthesis 
(6). The platinum pyrimidine complexes also interact with nucleic acids and pro- 
teins (2). The complexes appear to produce a partial denaturation of DNA and an 
almost complete destruction of protein secondary structure (16). The specificity 
of their complexing with nucleic acids is further demonstrated through the use of 
platinum complexes as nuclei acid stains for electron microscopy (19). Biological 
and chemical investigations of the platinum pyrimidine blues have been hampered 
because they are a mixture of oligomers of varying degrees of stability in solution, 
and only recently has the synthesis of a crystalline platinum blue been successful 
(15). The structural features elucidated are believed to be shared by all platinum 
blues. It is not unexpected that PTB proved to be a teratogen. Many chemothera- 
peutic agents are teratogenic, and they also inhibit DNA synthesis. The relation- 
ship between the inhibition of DNA synthesis and the production of malformations 
is not clear (20). It may be that interference with cell proliferation and induction 
of cell death that often follows inhibition of DNA synthesis is responsible for the 
production of malformations (21). Interference with protein synthesis usually 
shows little or no teratogenic effect (20). 
In summary, platinum thymine blue is both lethal and teratogenic to the 
developing rat embryo. Several criteria for teratogenic action are satisfied: a 
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dose response can be demonstrated, susceptibility changes with the stage of embry. 
onic development, and a correlation can be made with the defect produced and the 
stage of embryonic development at the time of treatment. PTB is a powerful in- 
hibitor of DNA synthesis, as are many other teratogens. The specific site and 
mechanism of teratogenic action of PTB in the induction of malformations, however, 
remains to be determined. 
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